Treat with foresight

Eylea® is the only approved anti-VEGF to successfully extend to 16-week treatment intervals in clinical trials with a T&E dosing regimen1,2

image
image

References:

  • EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; August 2019.
  • Ohji M, Ayame A, Takahashi K, Kobayashi M, Terano Y. Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96-week results of the ALTAIR study. Presented at: EURETINA 2018 Free Paper Sessions; September 2018; Vienna, Austria.
  • Ohji M. Intravitreal aflibercept treat-and-extend dosing for wet age-related macular degeneration: 96-week ALTAIR results. Presented at: 122nd Annual Meeting of the American Academy of Ophthalmology; October 27-30, 2018; Chicago, IL.
  • Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185.

This website contains information on EYLEA® (aflibercept solution for injection) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK. In countries outside the EU the local Product Information applies.

PP-EYL-ALL-0513-1. Last updated on 29/02/2020